Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
Malignant Ovarian Brenner Tumor
Explore 1 assets in Malignant Ovarian Brenner Tumor →Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Mayo Clinic
Modality
gene_therapy
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02068794CT.gov MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Malignant Ovarian Brenner Tumor
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter (this asset) | Mayo Clinic | P1/2 | CCC · 48 |
| Carboplatin | M.D. Anderson Cancer Center | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P3 | BB |
| Immunoglobulin G1-Kappa, Anti-(Homo Sapiens Csf1R (Colony Stimulating Factor 1 Receptor, Csf-1R, Csf-1-R, Macrophage Colonystimulating Factor 1 Receptor, C-Fms, Fms, Cd115)), Humanized Monoclonal Antibody | M.D. Anderson Cancer Center | P2 | CCC |
Other indications for Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Primary Peritoneal Carcinoma | — | P2 | B · 63 |
| Fallopian Tube Serous Adenocarcinoma | — | P2 | B · 59 |
| Fallopian Tube Mucinous Adenocarcinoma | — | P2 | B · 59 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- CarboplatinM.D. Anderson Cancer CenterBB
- Cis-Diamminedichloroplatinum IiNational Cancer Institute (NCI)BB
- Immunoglobulin G1-Kappa, Anti-(Homo Sapiens Csf1R (Colony Stimulating Factor 1 Receptor, Csf-1R, Csf-1-R, Macrophage Colonystimulating Factor 1 Receptor, C-Fms, Fms, Cd115)), Humanized Monoclonal AntibodyM.D. Anderson Cancer CenterCCC
Citation
Floatz Terminal. Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter in Malignant Ovarian Brenner Tumor. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/oncolytic-measles-virus-encoding-thyroidal-sodium-iodide-symporter-malignant-ovarian-brenner-tumor
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →